PHAR Earnings Date: Mar 11, 2027 (Estimated) — Pharming Group N.V.
NASDAQ · Healthcare · Biotechnology
Updated
When is PHAR's next earnings date?
Pharming Group N.V. (PHAR) is expected to report Q4 2026 earnings on Thursday, March 11, 2027 at 2:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.25 on revenue of $114.7M.
How did PHAR do in its last earnings report?
In its most recent report on Oct 27, 2026 (Q3 2026), Pharming Group N.V. posted EPS of $0.30 versus the $0.15 estimate, a beat of 100.0%. Revenue was $117.6M against a $117.6M estimate. The stock's 1-day post-earnings move was -0.3%.
How much does PHAR stock move after earnings?
PHAR beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.0% (up or down) in the day after earnings.
About Pharming Group N.V.
Pharming Group N.V. is a biopharmaceutical company dedicated to the creation and commercialization of protein replacement therapies and precision medicines. The firm concentrates its efforts on addressing rare diseases and critical unmet medical needs across the United States, Europe, and other international markets. Its primary commercialized product is Ruconest, a recombinant human C1 esterase inhibitor utilized for the acute treatment of hereditary angioedema. Pharming's development pipeline also includes rhC1INH, which is being investigated for conditions such as pre-eclampsia, acute kidney injury, and COVID-19. Additionally, the company is developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor designed for patients with activated PI3K delta syndrome, as well as an alpha-glucosidase therapy targeting Pompe and Fabry diseases. The company has established significant collaborations, including a development and licensing agreement with Novartis. It also maintains a strategic partnership with Orchard Therapeutics plc for the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy intended for hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
🤖 AI Earnings Analysis
Pharming’s 21% revenue growth to $117.6 million beat expectations, while Joenja expansion and November CVID data offer catalysts; this is a strong quarter, though the EPS beat is less persuasive given thin margins.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-27 | Q3 2026 | 0.15 | 0.30 | +100.00% | $117.6M | ✅ Beat | -0.25% | — | — |
| 2026-07-30 | Q2 2026 | 0.09 | 0.02 | -77.78% | $90.2M | ❌ Miss | -10.49% | -11.12% | -1.92% |
| 2026-05-07 | Q1 2026 | 0.01 | -0.07 | -800.00% | $72.4M | ❌ Miss | -26.83% | -20.91% | -23.53% |
| 2026-03-12 | Q4 2025 | 0.07 | 0.07 | +0.00% | $106.5M | ➖ Inline | -4.66% | -3.90% | +7.62% |
| 2025-11-06 | Q3 2025 | 0.02 | 0.10 | +400.00% | $97.3M | ✅ Beat | +11.53% | +30.12% | +27.09% |
| 2025-07-31 | Q2 2025 | -0.05 | 0.06 | +220.00% | $93.2M | ✅ Beat | +10.11% | +21.80% | +44.60% |
| 2025-05-08 | Q1 2025 | -0.03 | -0.22 | -633.33% | $79.1M | ❌ Miss | +11.22% | +1.67% | +31.75% |
| 2025-03-13 | Q4 2024 | 0.01 | 0.05 | +400.00% | $92.7M | ✅ Beat | +12.92% | +15.31% | +4.52% |
Showing last 8 quarters.